A Phase 3 Study of MP-424 in Combination With PEG-IFN Alfa-2a and RBV, in Subjects With Genotype 1 Hepatitis C, Who Are Treatment-Naive or Relapsed After Previous Treatment
Phase of Trial: Phase III
Latest Information Update: 01 May 2017
Price : $35 *
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 01 May 2017 Results published in the Hepatology Research
- 10 Dec 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 24 Jan 2014 Status changed from recruiting to active, no longer recruiting; according to ClinicalTrials.gov record.